BOSTON– Back Bay Life Science Advisors, an international partner for biopharma, medtech and healthtech companies and their investors, announced the opening of its new office in Toronto, Canada, to further support clients and partners located across the global life sciences and healthcare markets.
With a strong presence in Boston and Northern Europe, this North American expansion further strengthens Back Bay’s role in developing promising life science communities globally. In addition, its Canadian presence underscores Back Bay’s specialized market support in life science development and transaction execution in this country. Back Bay’s advisors are recognized industry experts on global biopharma, medtech and healthtech development, partnering and M&A.
“We are proud to join our clients and network in Canada’s dedicated, innovative and growing life sciences community,” said Jonathan P. Gertler, MD, CEO and Co-Founder, Back Bay Life Science Advisors. “We look forward to partnering with our Canadian clients directly from our new Toronto-based offices and to bringing our many years of experience to help advance Canadian life sciences and forge US-Canadian partnerships.”
Back Bay’s Canadian headquarters is located in one of North America’s leading innovation hubs, the MaRS Centre, recently named as one of the best workplaces in the world for innovators. Located in the heart of Toronto’s Discovery District, the MaRS Centre plays a key role in supporting one of the highest concentrations of science and tech minds in the world. Through its physical campus and affiliated programs, MaRS supports over 1,400 Canadian science and tech companies.
Back Bay founding member and Managing Director, Stephan Gauldie, PhD, leads Back Bay’s Canadian operations in close concert with founder Jonathan P. Gertler, who has familial and business ties to the Toronto community. Dr. Gauldie was integral in developing the unique continuum and integration of strategic advisory and investment banking execution offered only by Back Bay Life Science Advisors.
“Canadian science is at the forefront, with breakthroughs in cell and gene therapy, identification of novel disease targets for drug development, and in facilitating technologies such as artificial intelligence to drive drug discovery. These and many other advances, underpin Canada’s life sciences sector, and the early-stage biotech ecosystem is growing at a fantastic pace,” said Dr. Gauldie.
The Canadian biotechnology industry is one of the country’s premiere high technology sectors, acting as a strong engine of innovation, a source of highly skilled employment, and destination for investment capitali, and Toronto is a key hub for life science research, clinical trials and commercialization. Canada is internationally well positioned in this field, as it now accounts for almost 10% of the world’s biotechnology-related revenues and ranks second behind the US in number of biotechnology firmsii.
